Controlled US studies of fenofibrate in the treatment of dyslipidemias
Data from mostly open, non-comparative European studies indicate that fenofibrate reduces total plasma cholesterol by approximately 20–25% in patients with various types of hyperlipoproteinemias, and reduces total plasma triglycerides by approximately 30–60% in patients with hyperlipoproteinemia. We review here two recent randomized, double-blinded, placebo-controlled clinical trials conducted in the United States which confirmed the European findings, firstly in patients with Type IIa or IIb hyperlipoproteinemia, secondly in patients with type IV or type V hyperlipoproteinemia.
KeywordsPlasma Lipid Profile Fenofibrate Treatment Total Plasma Cholesterol Concentration Fenofibrate Therapy Fenofibrate Group
Unable to display preview. Download preview PDF.